Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | WNT1 | P04628 | 5/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23740932 | 0.79 | GSK3B (0.60) | GSK3BDYRK1AWNT1 | |
| SCHEMBL17768018 | 0.78 | CA12 (0.50) | DYRK1ACA12CA2CA9CA1 | |
| SCHEMBL7893993 | 0.77 | CA12 (0.54) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL23740959 | 0.75 | GSK3B (0.57) | GSK3BDYRK1AWNT1 | |
| SCHEMBL23741091 | 0.74 | GSK3B (0.68) | GSK3BDYRK1AWNT1 | |
| SCHEMBL1360325 | 0.73 | CA12 (0.62) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL8281998 | 0.72 | CA12 (0.51) | GSK3BDYRK1ACA12CA2CA9 | |
| SCHEMBL2405220 | 0.72 | CA12 (0.62) | GSK3BDYRK1ACA12CA2CA9 | |
| SCHEMBL11147956 | 0.71 | MAP4K4 (0.51) | CA12CA2CA9CA1LRRK2 | |
| SCHEMBL557850 | 0.71 | PDPK1 (0.57) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| WO-2019079626-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | MED-PATHWAYS II LIMITED (VG) | 2019-04-25 | — | — | US | disclosed |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | MED-PATHWAYS II LIMITED (VG) | 2019-04-25 | — | — | US | disclosed |
| WO-2019079626-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK2 | GSK3B 9/4885DYRK1A 1/4885CA12 3654/4885 |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK2 | GSK3B 9/4885DYRK1A 1/4885CA12 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.